SCHEMBL1017394

SCHEMBL1017394

O=C(CN1CCc2cc(N3CCOCC3)nnc2C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 6/20 0.41
HRH3 Q9Y5N1 8/20 0.40
HSD17B10 Q99714 5/20 0.39
HPGD P15428 4/20 0.39
CASP1 P29466 4/20 0.39
CASP7 P55210 4/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
RECQL P46063 1/20 0.37
ADRA1A P35348 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
PARP1 P09874 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016063 0.92 HRH3 (0.38) KDM4EALDH1A1HRH3HSD17B10MAPT
SCHEMBL1017527 0.82 HRH3 (0.41) KDM4EALDH1A1HRH3HSD17B10MAPT
SCHEMBL1020740 0.82 KDM4E (0.42) KDM4EALDH1A1HRH3HSD17B10RECQL
SCHEMBL1018360 0.81 KDM4E (0.46) KDM4EALDH1A1HRH3HSD17B10HPGD
SCHEMBL1020109 0.81 KDM4E (0.41) KDM4EALDH1A1HRH3HSD17B10RECQL
SCHEMBL1013701 0.77 HRH3 (0.41) KDM4EALDH1A1HRH3HSD17B10MAPT
SCHEMBL1017235 0.77 HSP90AB1 (0.47) KDM4EALDH1A1HRH3MAPTLMNA
SCHEMBL12952799 0.77 CNR2 (0.41) KDM4EALDH1A1HSD17B10HPGDCASP1
SCHEMBL4069495 0.76 SMO (0.40) KDM4EALDH1A1HRH3HSD17B10LMNA
SCHEMBL1017157 0.75 KDM4E (0.42) KDM4EALDH1A1HRH3MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
EP-1998620-A4 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2009-09-02 EP disclosed
EP-1998620-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES Neurogen Corporation (US) 2008-12-10 EP disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 KDM4E 2634/4885ALDH1A1 1229/4885HRH3 1/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 KDM4E 2634/4885ALDH1A1 1229/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.